Crossmark

Safety and efficacy of rituximab-based first line treatment of chronic GVHD

Crossref DOI link: https://doi.org/10.1038/s41409-018-0399-7

Published Online: 2018-12-05

Published Print: 2019-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Solomon, Scott R.

Sizemore, Connie A.

Ridgeway, Michelle

Zhang, Xu

Brown, Stacey

Holland, H. Kent

Morris, Lawrence E.

Solh, Melhem

Bashey, Asad
License Information

Text and Data Mining valid from 2018-12-05
More Information

Article History

Received: 26 April 2018

Revised: 22 September 2018

Accepted: 8 November 2018

First Online: 5 December 2018

Compliance with ethical standards

:

: The authors declare that they have no conflict of interest.